Table 1

Studies using stereotactic body radiotherapy (SBRT) for primary or centrally recurrent disease in the pelvis

StudyYear of publicationPrimary sitesPrimary vs recurrentType of studyPatients included (n)Notable outcomes
Albuquerque et al7 2019CervixPrimaryPhase II prospective15The study closed early (with 15/21 patients having received treatment) due to poorer than expected outcomes. 2-year LC 70%; 2-year OS 53%. Grade 3 or higher late GI of 27% at 2 years
Haas et al48 2012CervixPrimaryRetrospective51 year LC 100%. No grade 3 or higher toxicities
Hsieh et al49 2013CervixPrimaryRetrospective92 grade 3 toxicities (thrombocytopenia and diarrhea). 3-year LC 77.8%
Ito et al6 2019CervixPrimaryPhase I prospective622.5 Gy in three fractions determined to be tolerable fractionation with no dose-limiting toxicities
Kubicek et al50 2013Cervix (n=7), uterine (n=2), vaginal (n=2)PrimaryRetrospective11Median follow-up for surviving patients was 420 days. 8/11 patients alive at last follow-up, 1/11 with local recurrence. Two patients had acute toxicity (grade 2 dysuria and grade 2 GI); one patient with late toxicity (grade 3 GI bleed)
Lee et al4 2021CervixPrimaryRetrospective253-year LC 80.9%, PFS 40.9%, OS 77.1%. Five (20%) grade 3 toxicity (3 genitourinary, 3 GI)
Marnitz et al51 2013CervixPrimaryProspective11Five grade 3 hematologic toxicities, one grade 4 toxicity (leukopenia). No local recurrence at median follow-up of 6 months
Kunos et al9 2009Cervix (n=1), uterine (n=1), ovarian (n=3)RecurrenceRetrospective5Five case reports of locally recurrent gynecologic cancers treated with SBRT. No grade 3 toxicities reported
  • BED, biologic effective dose; GI, gastrointestinal; LC, local control; OS, overall survival; PFS, progression-free survival; SBRT, stereotactic body radiotherapy.